Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

NEW YORK, August 23, 2018 /PRNewswire/ -- Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

Read the full report: https://www.reportlinker.com/p05043169

Summary
Many countries are facing the challenge of an aging population, and there will be an increased number of people aged 50 and over – a high-risk age range for Colorectal Cancer (CRC). Over half of the incident cases of Colorectal Cancer (CRC) are diagnosed in patients over the age of 50. Colorectal Cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally, accounting for 0.77 million deaths in 2015.

The five-year prevalence population for Colorectal Cancer (CRC) in Asia-Pacific was 1.7 million in 2017. This figure has been gradually rising with the growing elderly population and increasingly Westernized lifestyles. However, growing awareness of the disease and associated risk factors together with the availability of free testing services for Colorectal Cancer (CRC) patients will increase early diagnosis and the treatment-receiving population, including targeted treatment, driving demand and contributing to market growth. Increasing affordability and healthcare access in India and China are also likely to contribute to the growth of the treatment-receiving pool significantly.

On the other hand, the poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The Colorectal Cancer (CRC) market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on the presence of various molecular aberrations. The marketed products landscape comprises a wide range of treatment options, including EGFR-targeted therapies, angiogenesis inhibitors, multiple kinase inhibitors and new chemotherapies.

The report "Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 – Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" details the key points (etiology, epidemiology, current treatment, products currently marketed and in pipeline, market drivers and barriers) driving the Colorectal Cancer (CRC) market in the five Asia-Pacific (APAC) markets: India, China, Australia, South Korea and Japan.

Scope
- The CRC Asia-Pacific market will be valued at $7.9 billion in 2024, growing from $5.3 billion in 2017 at a CAGR of 6%.
- How will immune checkpoint inhibitors such as Keytruda and Opdivo contribute to growth?
- What effect will patent expirations of currently branded therapies have on market value?
- The CRC pipeline is large and diverse, with a strong presence of mAbs and targeted therapies.
- What are the common targets and mechanisms of action of pipeline therapies?
- Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAF-mutant CRC patients?
- What implications will the increased focus on targeted therapies have on the future of CRC treatment?
- Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
- How have the late-stage therapies performed in clinical trials?
- How would the approval of encorafenib plus binimetinib to treat BRAF-mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
- The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
- How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
- How could changes in risk factors such as population age, obesity and lifestyle influence the market?
- Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under $10m to over $1 billion.
- How do deal frequency and value compare between target families and molecule types?
- What were the terms and conditions of key licensing deals?

Reasons to buy
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the CRC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
- Analyze the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict CRC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the CRC deals landscape by analyzing trends in licensing and co-development deals.

Read the full report: https://www.reportlinker.com/p05043169

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/colorectal-cancer-therapeutics-in-asia-pacific-markets-to-2024---launch-of-premium-targeted-therapies-and-increasing-prevalence-to-drive-the-market-300701818.html

SOURCE Reportlinker